financetom
Business
financetom
/
Business
/
XPeng sees better-than-expected quarterly revenue on new markets, cheaper SUVs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
XPeng sees better-than-expected quarterly revenue on new markets, cheaper SUVs
Mar 18, 2025 4:28 AM

(Reuters) - Chinese electric vehicle maker XPeng ( XPEV ) on Tuesday forecast first-quarter revenue above estimates, betting on the launch of its lower-priced G6 and G9 SUV models as well as its foray into European markets.

China has a hyper-competitive EV market where carmakers try to undercut the competition by offering a bevy of features at a much lower cost than their Western counterparts.

XPeng ( XPEV ) forecast first-quarter revenue of 15 billion yuan to 15.7 billion yuan, the midpoint of which is above analysts' average estimate of 14.86 billion yuan, according to data compiled by LSEG.

The Guangzhou-based company expects to deliver between 91,000 and 93,000 vehicles in the first quarter, which is about 317% to 326.2% higher than a year ago.

Earlier this month, XPeng ( XPEV ) revealed its refreshed G6 and G9 SUVs at prices lower than their previous models.

The new G6 starts at 176,800 yuan ($24,402), 11.6% lower than its predecessor, while the starting price of the G9 is 5.7% lower at 248,800 yuan, XPeng ( XPEV ) Chairman He Xiaopeng said at a press conference.

Both models are equipped with the proprietary Turing AI smart driving system without an extra charge, Xiaopeng said.

The company also signed agreements with distributors Inchcape and Hedin in Europe this month to enter the Polish, Swiss, Czech and Slovak markets.

XPeng ( XPEV ) is expected to break even sometime later in 2025, President Brian Gu had said in an interview with Reuters in November.

The company delivered 91,507 vehicles in the fourth quarter, up 52.1% from a year ago.

Revenue for the quarter ended December 31 was 16.11 billion yuan, beating estimates of about 16.02 billion yuan.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Trump's Semiconductor Tariff Rollout Likely Delayed
Market Chatter: Trump's Semiconductor Tariff Rollout Likely Delayed
Nov 19, 2025
02:17 PM EST, 11/19/2025 (MT Newswires) -- US officials are privately saying that President Donald Trump's promised semiconductor tariffs will not be levied soon, Reuters reported Wednesday, citing sources. Government officials informed government and private-industry stakeholders about the potential delay over the last several days, Reuters reported, citing two people with direct knowledge of the matter and a third person...
Update: AMD, Cisco, Saudi Arabia's Humain Form AI Data Center Venture
Update: AMD, Cisco, Saudi Arabia's Humain Form AI Data Center Venture
Nov 19, 2025
02:18 PM EST, 11/19/2025 (MT Newswires) -- (Updates with details from Humain in the first three paragraphs.) Advanced Micro Devices ( AMD ) and Cisco Systems ( CSCO ) agreed to form a joint venture with Saudi Arabia's Humain to build AI data centers. The venture plans to deploy up to 1 gigawatt of AI infrastructure by 2030, with a...
AI set to redefine shopping and payments, Affirm CEO says
AI set to redefine shopping and payments, Affirm CEO says
Nov 19, 2025
(Reuters) -Max Levchin, CEO and co-founder of Affirm, which offers buy now, pay later plans, said artificial intelligence is poised to transform shopping by taking over human tasks and making financial products more transparent. AI agents will soon be able to instantly weed out products with prohibitively high interest rates or late fees, forcing businesses to rethink fee structures, Levchin...
Johnson & Johnson's Janssen Gets FDA Approval for Darzalex in Amyloidosis
Johnson & Johnson's Janssen Gets FDA Approval for Darzalex in Amyloidosis
Nov 19, 2025
02:21 PM EST, 11/19/2025 (MT Newswires) -- Johnson & Johnson's ( JNJ ) Janssen Biotech unit has been granted traditional approval to Darzalex Faspro with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis, the US Food and Drug Administration said Wednesday. The approval for Darzalex, with active ingredients daratumumab and hyaluronidase-fihj, was based on major organ deterioration progression...
Copyright 2023-2026 - www.financetom.com All Rights Reserved